Not everyone agrees that payers should risk losing these healthier consumers for the long haul.
When a CareFirst BlueCross BlueShield subsidiary decided recently to stop selling bronze plans in Virginia, it raised the question: is this the beginning of the end?
For some time, there has been concern about bronze plans for 2 reasons: the bargain-basement price comes with coverage that calls for large out-of-pocket costs, leaving the most price-sensitive consumers exposed if there’s a major health event, like cancer. Under the Affordable Care Act, bronze plans must pay 60% of coverage costs; silver plans, the next product level, must play 70% of costs.
But the bigger concern is that the bronze tier attracted the youngest, healthiest consumers, who paid less premium, while older and sicker consumers migrated to higher-level plans. That’s made it challenging for payers to make money off generally, but off the bronze plans especially.
According to Kaiser Health News, the lack of growth in the bronze tier—the number of plans increased less than 1% from last year—suggested insurers were looking for a way out of a money-losing product. Information from the Robert Wood Johnson Foundation found that the number of silver plans grew 2.9%.
Already, there are questions whether other insurers will follow CareFirst’s lead. In Virginia, the payer plans to transition bronze plan members into silver plans next year while offering bronze plans in other states, according to the KHN report and Fierce HealthPayer.
A senior director from Leavitt Partners told Fierce HealthPayer that if bronze plans went away, it could be destabilizing for the market; these price-sensitive enrollees might stop buying coverage altogether, said Sean Mullin.
For some time, insurers in several states have said they are seeing more high-cost enrollees than they expected. In late March, the Blue Cross Blue Shield Association issued a report on healthcare utilization among new enrollees under the ACA; the report found new enrollees needed significantly more medical care than existing clients in both individual and employer-based plans. Costs for these new enrollees were 19% higher than those in employer plans in 2014 and 22% higher in 2015.
Not everyone thinks dropping bronze plans is a good long-term strategy for payers. Keeping these healthier enrollees might be beneficial, rather than risk losing them altogether.
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More